Table 2.
Patient characteristics, treatments received, and treatment‐related outcomes in the subgroup of patients with EBV‐positive disease
| Patient | Gender | Age | No. of treatment lines | Treatment regimen | Best responsea | No. of treatment cycles | Individual patient PFS, months | Individual patient OS, months |
|---|---|---|---|---|---|---|---|---|
| 013 | M | 65 | 1 | Docetaxel + oxaliplatin | CR | 6 | 51.8 | 52.8b |
| 031 | M | 81 | 0 | NAc | NA | NA | NA | 3.7b |
| 032 | M | 59 | 1 | FOLFOX | CR | 5 | 2.6d | 5.6b |
| 035 | F | 69 | 1 | CAPOX | CR | 8 | 93.3 | 95.0b |
| 068 | M | 67 | 1 | FOLFOX | PR | 10 | 56.8 | 66.9b |
| 156 | M | 69 | 2 | FOLFOX (first line) | PR | 12 | 12.0 | 42.1 |
| Paclitaxel + ramucirumab (second line) | SD | 6 | 6.4 | |||||
| 172 | M | 74 | 2 | FOLFOX (first line) | PR | 11 | 8.2 | 25.2 |
| Paclitaxel + ramucirumab (second line) | SD | 8 | 3.3 |
a
Response were evaluated according to RECIST 1.1.
b
Patient alive and progression‐free at time of data cutoff (November 15, 2019).
c
This patient received only best supportive care.
d
Patient still on treatment at time of data cutoff (November 15, 2019).
Abbreviations: CR, complete response; F, female; M, male; NA, not applicable; PR, partial response; SD, stable disease.